General Pharmacology Practice Questions

Q: The apparent volume of distribution (Vd) of a drug exceeds the total body fluid volume if the drug is:

Sequestrated in body tissues. **Explanation:** The **Apparent Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($Vd = \text{Amount of drug} / \text{Plasma concentration}$). **Why Option A is correct:** If a drug is highly lipid-soluble or has a high affinity for specific tissues (e.g., adipose tissue, muscle, or bone), it leaves the vascular compartment and becomes **sequestrated in body tissues**. This results in a very low plasma concentration. Since $Vd$ is inversely proportional to plasma concentration, a low denominator leads to a $Vd$ that can far exceed the total body water (~42L). For example, Digoxin has a $Vd$ of ~500L because it binds extensively to cardiac and skeletal muscle. **Why the other options are incorrect:** * **Option B:** Elimination rate (half-life) affects how long a drug stays in the body, but it does not determine the initial distribution pattern between plasma and tissues. * **Option C:** Poor plasma solubility usually implies high lipid solubility, but the $Vd$ only increases if the drug actually binds to or dissolves in extravascular tissues. * **Option D:** Drugs **highly bound to plasma proteins** (e.g., Warfarin) are "trapped" in the vascular compartment. This maintains a high plasma concentration, resulting in a **low Vd**. **High-Yield NEET-PG Pearls:** * **Low Vd ( 42L):** Drugs sequestered in tissues (e.g., Chloroquine, Digoxin, Morphine). * **Clinical Significance:** Drugs with a high Vd are **not** easily removed by hemodialysis because most of the drug is outside the blood.

Q: Rate of absorption of an intramuscular injection is determined by which of the following factors?

Vascularity. **Explanation:** The rate of absorption of a drug from an intramuscular (IM) site is primarily determined by the **vascularity** (blood flow) of the muscle. 1. **Why Vascularity is Correct:** Absorption from an IM site occurs via simple diffusion from the muscle interstitial fluid into the capillaries. The rate-limiting step for small, water-soluble molecules is the **blood flow** to the area. Muscles with higher vascularity (e.g., Deltoid) exhibit faster absorption rates compared to those with lower vascularity (e.g., Gluteus maximus). This is also why exercise, which increases regional blood flow, accelerates IM drug absorption. 2. **Why Other Options are Incorrect:** * **Molecular Weight:** While it affects the *mechanism* of absorption (large molecules enter via lymphatics), the primary determinant of the *rate* in clinical IM administration is perfusion, not the size of the molecule. * **Volume of the Drug:** Volume primarily affects the pressure at the injection site and potential tissue damage/pain, but it does not dictate the physiological rate of systemic uptake. * **Bore of the Needle:** This determines the ease of administration (viscosity management) and patient discomfort, but has no physiological impact on how the drug crosses the capillary membrane once deposited. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Absorption Rate:** Deltoid > Vastus lateralis > Gluteus maximus (due to decreasing vascularity). * **Depot Preparations:** Drugs like Penicillin G Benzathine or Haloperidol Decanoate are designed as insoluble salts in oil to *intentionally* slow down absorption despite high vascularity. * **Shock/Hypotension:** In patients with circulatory collapse, IM absorption is significantly impaired due to peripheral vasoconstriction; hence, the **Intravenous (IV)** route is preferred in emergencies.

Q: Which of the following is an immunostimulant agent?

Levamisole. **Explanation:** **Levamisole** is the correct answer. Originally developed as an anthelmintic, it is a potent **immunomodulator** that acts as an **immunostimulant**. It works by restoring depressed T-cell and macrophage functions, enhancing phagocytosis, and stimulating chemotaxis. While its use has largely been superseded by newer agents, it was historically used in conditions like colon cancer (as an adjuvant with 5-Fluorouracil) [1] and certain autoimmune disorders. **Analysis of Incorrect Options:** * **Pirenzepine (A):** This is a selective **M1 muscarinic receptor antagonist**. It was traditionally used to reduce gastric acid secretion in peptic ulcer disease but is rarely used now due to the advent of PPIs. * **Albendazole (C):** A broad-spectrum **anthelmintic** agent. It works by inhibiting microtubule synthesis (binding to β-tubulin) in parasites. Unlike levamisole, it does not possess significant immunostimulant properties. * **Methotrexate (D):** A folate antimetabolite that acts as an **immunosuppressant** and cytotoxic agent [2]. It inhibits dihydrofolate reductase (DHFR) and is used in cancer chemotherapy and autoimmune diseases like Rheumatoid Arthritis [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Levamisole in Pediatrics:** It is still frequently used in the management of **Steroid-Dependent Nephrotic Syndrome (SDNS)** to maintain remission. * **Side Effects:** A classic side effect of levamisole is **agranulocytosis** [1]; it has also been associated with multifocal leukoencephalopathy. * **Other Immunostimulants:** Remember **Thalidomide** (in Erythema Nodosum Leprosum) [1], **Isoprinosine**, and **Cytokines** (Interferons, IL-2) as other important agents in this category.

Q: Pharmacodynamics includes:

Mechanism of action. **Explanation:**Pharmacology is broadly divided into two main branches: **Pharmacokinetics** and **Pharmacodynamics**.**1. Why the Correct Answer is Right:** **Pharmacodynamics** is defined as "what the drug does to the body." [3] It focuses on the biochemical and physiological effects of drugs and their **mechanisms of action** [1]. This includes drug-receptor interactions, signal transduction pathways (like G-protein coupled receptors), and the relationship between drug concentration and effect (dose-response curves) [2].**2. Why the Incorrect Options are Wrong:** Options A, B, and C all fall under the umbrella of **Pharmacokinetics**, which is "what the body does to the drug."* **Drug Absorption (C):** The movement of a drug from its site of administration into the bloodstream.* **Drug Elimination (A) & Excretion (B):** Elimination is the irreversible removal of a drug from the body, which occurs via **Metabolism** (biotransformation, primarily in the liver) and **Excretion** (primarily via the kidneys).**High-Yield NEET-PG Pearls:** * **Mnemonic:** Remember **ADME** for Pharmacokinetics (**A**bsorption, **D**istribution, **M**etabolism, **E**xcretion).* **Receptor Regulation:** A key pharmacodynamic concept is *Down-regulation* (prolonged agonist use leads to decreased receptor number/sensitivity) and *Up-regulation* (prolonged antagonist use leads to increased receptor sensitivity).* **Therapeutic Index (TI):** A pharmacodynamic parameter calculated as $TD_{50} / ED_{50}$. A narrow TI (e.g., Lithium, Digoxin, Warfarin) requires Therapeutic Drug Monitoring (TDM).* **Potency vs. Efficacy:** Efficacy (the maximum response a drug can produce) is clinically more important than potency (the amount of drug needed to produce an effect).

Q: All of the following are Phase II reactions except?

Cyclization. **Explanation:** Drug metabolism (biotransformation) typically occurs in two phases. **Phase I (Nonsynthetic) reactions** involve the introduction or unmasking of a functional group (–OH, –NH2, –SH), while **Phase II (Synthetic) reactions** involve the attachment of an endogenous moiety to the drug to make it more water-soluble for excretion. **Why Cyclization is the correct answer:** Cyclization is a **Phase I reaction**. It involves the formation of a ring structure from an open-chain compound (e.g., proguanil to cycloguanil). Other Phase I reactions include Oxidation (most common), Reduction, Hydrolysis, and Decarboxylation. **Analysis of Incorrect Options (Phase II Reactions):** Phase II reactions involve **conjugation**. * **A. Acetylation:** A Phase II reaction mediated by N-acetyltransferase (e.g., Isoniazid, Hydralazine). * **B. Methylation:** A Phase II reaction (e.g., Adrenaline to Metanephrine). * **C. Glycine conjugation:** A Phase II reaction (e.g., Salicylates conjugated with glycine to form hippuric acid). * *Other Phase II reactions include Glucuronidation (most common), Sulfation, and Glutathione conjugation.* **High-Yield NEET-PG Pearls:** 1. **Glucuronidation** is the most common Phase II reaction and the only one that occurs in the microsomal fraction (smooth ER); others are non-microsomal. 2. **Oxidation** is the most common Phase I reaction, primarily mediated by **Cytochrome P450** enzymes. 3. **Phase II before Phase I:** While the sequence is usually I then II, some drugs like **Isoniazid** undergo Phase II (Acetylation) followed by Phase I (Hydrolysis). 4. **Slow Acetylators:** Genetic polymorphism in acetylation (NAT2 enzyme) can lead to toxicity with drugs like Isoniazid (peripheral neuropathy) and Hydralazine (Lupus-like syndrome).

Q: An antagonist that generates an action opposite to a substance by binding to different receptors is known as:

Physiological antagonist. ### Explanation **1. Why Physiological Antagonist is Correct:** A **physiological (or functional) antagonist** occurs when two drugs act on **different receptors** and produce **oppositely directed** physiological effects on the same system. Unlike pharmacological antagonism, there is no competition for the same receptor site. Instead, the drugs activate independent pathways that cancel each other out functionally. * *Classic Example:* **Histamine** (acts on H1 receptors to cause bronchoconstriction) vs. **Adrenaline** (acts on β2 receptors to cause bronchodilation). **2. Why Other Options are Incorrect:** * **Physical Antagonist (A):** Based on the physical property of the drug. For example, **Charcoal** adsorbs alkaloids, preventing their absorption. * **Chemical Antagonist (B):** Two substances react chemically to form an inactive product. No receptors are involved. For example, **Chelating agents** (EDTA) binding to heavy metals or **Antacids** neutralizing gastric acid. * **Pharmacologic Antagonist (D):** The antagonist binds to the **same receptor** as the agonist, preventing the agonist from binding. This can be competitive (reversible) or non-competitive (irreversible). **3. NEET-PG Clinical Pearls & High-Yield Facts:** * **Adrenaline in Anaphylaxis:** Adrenaline is the "physiological antagonist" of histamine and is the drug of choice for anaphylactic shock because it rapidly reverses life-threatening airway obstruction and hypotension via different receptors. * **Glucagon and Insulin:** These are physiological antagonists regarding blood glucose levels (Glucagon increases glucose via glucagon receptors; Insulin decreases it via insulin receptors). * **Key Distinction:** If the question mentions "same receptor," think **Pharmacologic**; if it mentions "different receptor/same system," think **Physiological**.

Q: The skeletal muscle relaxant, vecuronium, acts at cholinergic receptors where it exhibits:

Affinity but no efficacy. ### Explanation **1. Why Option A is Correct:** Vecuronium is a **competitive (non-depolarizing) neuromuscular blocker**. In pharmacology, an **antagonist** is defined as a drug that has **affinity** (the ability to bind to a receptor) but lacks **intrinsic activity/efficacy** (the ability to activate the receptor and produce a biological response). Vecuronium competes with acetylcholine (ACh) for the nicotinic receptors ($N_m$) at the neuromuscular junction. By binding to the receptor without activating it, it prevents ACh from binding, thereby inhibiting muscle contraction and causing paralysis. **2. Why Other Options are Incorrect:** * **Option B (Efficacy but no affinity):** This is pharmacologically impossible. A drug must first have affinity (bind) to a receptor before it can exert any efficacy. * **Option C (Receptor upregulation):** While chronic blockade of receptors can lead to upregulation (an increase in receptor number), this is a long-term compensatory mechanism and not the primary mechanism of action of vecuronium. * **Option D (Affinity and efficacy):** This describes an **agonist**. Succinylcholine (a depolarizing blocker) initially shows affinity and efficacy (causing fasciculations) before causing a block. Vecuronium, being non-depolarizing, has no efficacy. **3. NEET-PG Clinical Pearls:** * **Reversibility:** The action of vecuronium can be reversed by Acetylcholinesterase inhibitors like **Neostigmine**, which increase ACh levels to outcompete the blocker. * **Sugammadex:** A specific reversal agent that encapsulates vecuronium molecules, rendering them inactive. * **Metabolism:** Vecuronium is primarily excreted via **bile** (partially metabolized by the liver), making it safer than pancuronium in patients with renal failure. * **Cardiovascular Stability:** Unlike d-tubocurarine, vecuronium does not cause significant histamine release or ganglion blockade, ensuring hemodynamic stability.

Q: Succinylcholine is contraindicated in all the following conditions except:

Rapid sequence intubation. **Explanation:** Succinylcholine is a **depolarizing neuromuscular blocker** that acts as an agonist at the nicotinic acetylcholine receptors (nAChR). Its primary clinical utility is in **Rapid Sequence Intubation (RSI)** because of its rapid onset (30–60 seconds) and short duration of action (5–10 minutes), allowing for quick airway control. **Why Option C is Correct:** Rapid sequence intubation is the **primary indication** for Succinylcholine, not a contraindication. It is preferred in emergency settings where the patient has a "full stomach" to prevent aspiration. **Why Other Options are Contraindicated:** The common mechanism for contraindication in options A, B, and D is the risk of **life-threatening hyperkalemia**. * **Burns (Option A):** After 24–48 hours of a major burn, there is an "upregulation" of extrajunctional acetylcholine receptors. Succinylcholine causes prolonged depolarization of these receptors, leading to a massive efflux of potassium. * **Muscular Dystrophy (Option B):** In conditions like Duchenne muscular dystrophy, Succinylcholine can cause rhabdomyolysis, hyperkalemia, and cardiac arrest. * **Neuromuscular Disease (Option D):** Conditions like stroke, spinal cord injury, or prolonged immobilization also lead to receptor upregulation, making the patient highly susceptible to hyperkalemic cardiac arrest. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Agonist at nAChR causing persistent depolarization (Phase I block). * **Metabolism:** Rapidly hydrolyzed by **Pseudocholinesterase** (Butyrylcholinesterase). * **Side Effects:** Muscle fasciculations (can be prevented by a small dose of non-depolarizing blocker), malignant hyperthermia (treated with **Dantrolene**), and increased intraocular/intragastric pressure. * **Genetic Variation:** Patients with atypical pseudocholinesterase experience prolonged apnea after Succinylcholine administration.

Question 1

The apparent volume of distribution (Vd) of a drug exceeds the total body fluid volume if the drug is:

Accepted Answer

Sequestrated in body tissues

Answer

Slowly eliminated from the body

Answer

Poorly soluble in plasma

Answer

Highly bound to plasma proteins

Question 2

Rate of absorption of an intramuscular injection is determined by which of the following factors?

Accepted Answer

Vascularity

Answer

Molecular weight of the drug

Answer

Volume of the drug

Answer

Bore of the needle

Question 3

Which of the following is an immunostimulant agent?

Accepted Answer

Levamisole

Answer

Pirenzepine

Answer

Albendazole

Answer

Methotrexate

Question 4

A drug that binds to a receptor at a site distinct from the active site and alters the affinity of the receptor for the endogenous ligand is a:

Accepted Answer

Allosteric modulator

Answer

Competitive antagonist

Answer

Inverse agonist

Answer

Partial agonist

Question 5

Pharmacodynamics includes:

Accepted Answer

Mechanism of action

Answer

Drug elimination

Answer

Drug excretion

Answer

Drug absorption

Question 6

All of the following are Phase II reactions except?

Accepted Answer

Cyclization

Answer

Acetylation

Answer

Methylation

Answer

Glycine conjugation

Question 7

Which of the following best describes chrono-pharmacology?

Accepted Answer

The study of time-dependent effects of drugs on the body's rhythms.

Answer

The study of the relationship between drug dosage and its effects.

Answer

The study of unintended or harmful effects of drugs.

Answer

The study of drugs derived from natural sources.

Question 8

An antagonist that generates an action opposite to a substance by binding to different receptors is known as:

Accepted Answer

Physiological antagonist

Answer

Physical antagonist

Answer

Chemical antagonist

Answer

Pharmacologic antagonist

Question 9

The skeletal muscle relaxant, vecuronium, acts at cholinergic receptors where it exhibits:

Accepted Answer

Affinity but no efficacy

Answer

Efficacy but no affinity

Answer

Receptor upregulation

Answer

Affinity and efficacy

Question 10

Succinylcholine is contraindicated in all the following conditions except:

Accepted Answer

Rapid sequence intubation

Answer

Burns

Answer

Muscular dystrophy

Answer

Neuromuscular disease

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?